Patents by Inventor CHIKAKO OGAWA

CHIKAKO OGAWA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS
    Publication number: 20180354939
    Abstract: Embodiments of the disclosure relate to selectively substituted quinolone compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
    Type: Application
    Filed: August 22, 2018
    Publication date: December 13, 2018
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: J. Eric Carlson, Hans Hansen, Lynn Hawkins, Sally Ishizaka, Matthew Mackey, Shawn Schiller, Chikako Ogawa, Heather Davis, Atsushi Endo
  • Selectively substituted quinoline compounds
    Patent number: 10087174
    Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: October 2, 2018
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: J. Eric Carlson, Lynn Hawkins, Sally Ishizaka, Shawn Schiller, Chikako Ogawa, Atsushi Endo
  • SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS
    Publication number: 20180030045
    Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
    Type: Application
    Filed: August 7, 2017
    Publication date: February 1, 2018
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: J. Eric CARLSON, Hans HANSEN, Lynn HAWKINS, Sally ISHIZAKA, Matthew MACKEY, Shawn SCHILLER, Chikako OGAWA, Heather DAVIS, Atsushi ENDO
  • Selectively substituted quinoline compounds
    Patent number: 9663486
    Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: May 30, 2017
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Roch Boivin, Hans Hansen, Sally Ishizaka, Matthew Mackey, Shawn Schiller, Chikako Ogawa, Sridhar Narayan, Peter Bertinato, Gregory Berger, Atsushi Endo, Robert T. Yu, Lynn Hawkins
  • (Hetero) arylacrylamides for the control of ectoparasites
    Patent number: 9491941
    Abstract: The present invention relates to new compounds of formula (I) wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (I) are useful in the control of parasites, in particular ectoparasites, in and on vertebrates.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: November 15, 2016
    Assignee: NOVARTIS TIERGESUNDHEIT AG
    Inventors: Emilie Dupont, Noelle Gauvry, Steve Nanchen, Chikako Ogawa, Chouaib Tahtaoui
  • SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS
    Publication number: 20160326161
    Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
    Type: Application
    Filed: July 27, 2016
    Publication date: November 10, 2016
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Eric CARLSON, Hans HANSEN, Lynn HAWKINS, Sally ISHIZAKA, Matthew MACKEY, Shawn SCHILLER, Chikako OGAWA, Heather DAVIS, Atsushi ENDO
  • Selectively substituted quinoline compounds
    Patent number: 9428495
    Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: August 30, 2016
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Eric Carlson, Hans Hansen, Lynn Hawkins, Sally Ishizaka, Matthew Mackey, Shawn Schiller, Chikako Ogawa, Heather Davis, Atsushi Endo
  • SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS
    Publication number: 20160176841
    Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
    Type: Application
    Filed: October 14, 2014
    Publication date: June 23, 2016
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Roch BOIVIN, Hans HANSEN, Sally ISHIZAKA, Matthew MACKEY, Shawn SCHILLER, Chikako OGAWA, Sridhar NARAYAN, Peter BERTINATO, Gregory BERGER, Atsushi ENDO, Robert T. YU, Lynn HAWKINS
  • (HETERO) ARYLACRYLAMIDES FOR THE CONTROL OF ECTOPARASITES
    Publication number: 20150320044
    Abstract: The present invention relates to new compounds of formula (I) wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (I) are useful in the control of parasites, in particular ectoparasites, in and on vertebrates.
    Type: Application
    Filed: December 20, 2013
    Publication date: November 12, 2015
    Inventors: Emilie Dupont, Noelle Gauvry, Steve Nanchen, Chikako Ogawa, Chouaib Tahtaoui
  • SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS
    Publication number: 20150105370
    Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 16, 2015
    Inventors: ERIC CARLSON, HANS HANSEN, LYNN HAWKINS, SALLY ISHIZAKA, MATTHEW MACKEY, SHAWN SCHILLER, CHIKAKO OGAWA, HEATHER DAVIS
  • Selectively substituted quinoline compounds
    Patent number: RE47193
    Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: January 8, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: J. Eric Carlson, Hans Hansen, Lynn Hawkins, Sally Ishizaka, Matthew Mackey, Shawn Schiller, Chikako Ogawa, Heather Davis, Atsushi Endo